![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA
Department of Pharmacology, Asahikawa Medical College, Asahikawa, Japan (K.Y., F.U.); Pharmaceutical Research Center, School of Pharmacy, Iwate Medical University, Iwate, Japan (H.N.); DDS Institute, Jikei University School of Medicine, Tokyo, Japan (A.U.); Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan (H.K., F.K.); Department of Pharmacology, Faculty of Medicine (S.N.) and Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences (Y.S.), Kyoto University, Kyoto, Japan; Department of Applied Biochemistry, Tokai University, Kanagawa, Japan (M.M.); and Basic Research Division, Kitasato Institute, Tokyo, Japan (S.O.)
Received November 19, 2007; accepted January 31, 2008.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). Zymosan is known as a potent activator of the complement system (Pillemer et al., 1954), and its carbohydrate components β-1,3-glucan and mannan are responsible for both the alternative and lectin pathways of complement activation. In the alternative pathway, zymosan directly activates the complement system (Pillemer et al., 1954). In the lectin pathway, binding of mannose-binding lectin or ficolins to zymosan initiates complement activation in association with mannose-binding lectin-associated serine proteases (Fujita et al., 2004). Activation of the complement system liberates active components that enhance vascular permeability and induce inflammatory cell migration, contributing to the development of inflammation. In addition to complement activation, nonopsonized zymosan directly activates macrophages through several types of receptors, such as the type-3 complement receptor (Gordon, 2002) and the β-glucan receptor dectin-1 (Brown and Gordon, 2001). Activated macrophages then produce proinflammatory mediators, including eicosanoids, such as prostaglandins (PGs) and leukotrienes (LTs), platelet-activating factor (PAF), and inflammatory cytokines, further contributing to the development of inflammation.
Prostanoids, consisting of PGs and thromboxane, are the metabolites of arachidonic acid, and they exert a variety of actions throughout the body. Among these, the roles of prostanoids as inflammatory mediators have been extensively studied (Rocha e Silva, 1978), and it is well established that nonsteroidal anti-inflammatory drugs, such as aspirin and indomethacin, exert their anti-inflammatory effect by inhibiting cyclooxygenases (COXs), rate-limiting enzymes in prostanoid biosynthesis (Vane et al., 1998). Among prostanoids, PGE2 and PGI2 have been implicated as the prostanoids most responsible for inflammation because they have been detected abundantly in inflammatory exudates and tissues (Harada et al., 1982), and because they show a range of proinflammatory activity when administered in vivo (Rocha e Silva, 1978). Prostanoids act on their specific receptors expressed in various organs and tissues (Narumiya et al., 1999). PGE2 acts on four types of receptors, EP1, EP2, EP3, and EP4, and PGI2 acts on IP. Recent studies using mice lacking each of these receptors have confirmed some of the roles of PGE2 and PGI2 as inflammatory mediators, such as fever generation (Ushikubi et al., 1998) and inflammatory pain transmission (Murata et al., 1997), respectively. However, the role(s) of individual prostanoids is not precisely known in specific inflammatory conditions, including those accompanying innate immune responses.
An increase in vascular permeability is the hallmark for the presence of local inflammation, which then leads to edema formation or exudate accumulation. Zymosan-induced pleurisy and peritonitis have long been used as important models to examine the mechanisms of fungal-induced inflammation by evaluating exudate formation and leukocyte infiltration. Furthermore, a method to assess both the rate and degree of exudate formation has been established in pleurisy models (Vinegar et al., 1973). In a recent study, zymosan-engaged dectin-1 has been reported to regulate the activity of type IVA cytosolic phospholipase A2, a key enzyme liberating arachidonic acid upon inflammation, and the COX-2 expression in mouse peritoneal macrophages (Suram et al., 2006). Furthermore, significant production of prostanoids in zymosan-induced peritonitis has been reported (Lundy et al., 1990; Rao et al., 1994), suggesting the participation of prostanoids in zymosan-evoked innate immune responses. However, in zymosan-induced rat pleurisy, we could not determine the participation of prostanoids, whereas an initial activation of the complement system followed by PAF formation was found to be critical for accumulation of pleural exudates (Imai et al., 1991). As a result, the role of prostanoids in zymosan-induced responses remains to be determined.
In the present study, we clarify the roles of prostanoids, as well as their interaction with the complement system, in zymosan-induced pleurisy using mice lacking EP1, EP2, EP3, EP4, or IP. We also demonstrate the important role of the PGI2-IP system together with the complement system in zymosan-induced innate immune responses.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Segi et al., 1998; Ushikubi et al., 1998; Hizaki et al., 1999). All mice, including wild-type (WT) control mice, but with the exception of EP4–/– mice, have the genetic background of C57BL/6 mice. EP4–/– and their control F2-WT mice have a mixed genetic background of 129/Ola and C57BL/6 (Segi et al., 1998). Mice lacking the PAF receptor (PAFR–/– mice) (Ishii et al., 1998) were kindly donated by Dr. T. Shimizu (Tokyo University, Tokyo, Japan). All experiments were approved by the Asahikawa Medical College Committee on Animal Research, and they were carried out using 15- to 30-week-old male mice.
Zymosan-Induced Pleurisy. Zymosan (zymosan A from S. cerevisiae; Sigma-Aldrich, St. Louis, MO) was suspended in physiological saline at a concentration of 2%, and then it was autoclaved. Under ether anesthesia, pleurisy was induced by injecting 50 µlof 2% zymosan suspension into the mouse pleural cavity with a 25-gauge needle, whose tip had been blunted to avoid injury of the lung. Immediately after the mice had been killed at indicated times after the zymosan injection, pleural exudates were collected, and their volumes were measured. Next, the saline (0.5 ml) wash of the pleural cavity was collected, and it was combined with the collected exudates in a tube containing 50 µl of 3.8% sodium citrate solution. Leukocyte numbers in the pleural exudates were counted with a microcell counter (F820; Sysmex, Kobe, Japan), and leukocyte classification of a Giemsa-stained smear of the exudates was performed under a microscope (Imai et al., 1991). To assess the exudation rate, we injected pontamine sky blue (Tokyo Kasei, Tokyo, Japan) solution at a dose of 50 mg/kg into the tail vein 20 min before the designated time of sample collection. Concentrations of the dye in the collected pleural exudates and plasma were measured, and the rate of plasma exudation into the pleural cavity was calculated (Dozen et al., 1989).
To examine the involvement of prostanoids in zymosan-induced pleurisy, indomethacin (Sigma-Aldrich), which inhibits both COX-1 and COX-2, was prepared as a 1 mg/ml solution in 0.5% sodium carboxymethyl cellulose (Tokyo Kasei), and it was administered i.p. at a dose of 5 mg/kg 30 min before the zymosan injection. To examine the COX-2 contribution, SC58125 (Cayman Chemical, Ann Arbor, MI), a COX-2 inhibitor, was prepared as a 10 mg/ml solution in dimethyl sulfoxide, and it was administered i.p. at a dose of 10 mg/kg 30 min before the zymosan injection.
Measurement of PGs. The exudates collected at 1, 3, 5, and 24 h after the zymosan injection were frozen, and then they were stored at –80°C until use. The amounts of 6-keto-PGF1
, a stable metabolite of PGI2, and PGE2 in the exudates were measured using enzyme-linked immunosorbent assay kits (Cayman Chemical).
Western Blot Analysis for C3-Related Peptides. WT mice received injections intrapleurally with 50 µl of 2% zymosan suspension, and pleural exudates and blood samples were collected at indicated times. Blood was collected in the presence of anticoagulants, and plasma was prepared by centrifugation of blood. The exudate sample at 0 h was prepared using a wash of the pleural cavity with 0.6 ml of saline containing anticoagulants, because the exudates could not be obtained at this time point. The pleural exudates and plasma were subjected to 10% SDS-PAGE under reducing conditions with 4 µg proteins/lane, followed by transfer onto an Immobilon-P membrane (Millipore Corporation, Billerica, MA). After a blocking procedure with nonfat dry milk (Carnation, Solon, OH), the membrane was incubated with a goat antiserum against mouse complement C3 (Cappel, ICN, Aurora, OH) for 1 h at room temperature, followed by incubation with a peroxidase-conjugated rabbit affinity-purified antibody to goat IgG (Cappel, ICN). After washing, C3-related peptides were detected by enhanced chemiluminescence (GE Healthcare, Piscataway, NJ).
Depletion of Blood C3. To deplete blood C3, cobra venom factor (CVF; partially purified compound from venom of Naja Kaouthia; Venom Supplies, Tanunda, SA, Australia) was prepared as a 0.1 mg/ml solution in physiological saline, and it was administered i.p. at a dose of 10 µg for 24 h before the zymosan injection according to standard methodology (Cochrane et al., 1970).
PAF-Induced Pleurisy. C16-PAF and methylcarbamyl (MC)-PAF (Cayman Chemical) were prepared as 0.1 mg/ml solutions in phosphate-buffered saline containing 1% ethanol and 0.1% bovine serum albumin, and they were stored at –30°C until use. At the time of use, C16-PAF or MC-PAF solution was diluted to a concentration of 4 µg/ml with phosphate-buffered saline containing 0.1% bovine serum albumin. PAF pleurisy was induced by injecting 25 µl of C16-PAF or MC-PAF solution into the pleural cavity. The volume of the pleural exudates was measured 30 min after an injection of C16-PAF or MC-PAF. TCV-309 (Takeda Pharmaceutical, Osaka, Japan), a PAFR antagonist, was prepared as a 0.1 mg/ml solution in physiological saline, and it was administered i.p. at a dose of 1 mg/kg 30 min before the injection of C16-PAF or MC-PAF. When examining the involvement of PAF in zymosan-induced pleurisy, TCV-309 was injected i.p. at a dose of 1 mg/kg 30 min before the zymosan injection.
Statistical Analysis. Data are expressed as the mean ± S.E.M. Statistical analysis was carried out using Student's t test or one-way analysis of variance followed by Dunnett's t test. Differences with a value of p < 0.05 were considered statistically significant.
|
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Indomethacin treatment in WT mice attenuated exudate formation significantly throughout the time course (Fig. 1A); the peak exudate volume at 5 h was decreased from 524 ± 14 (n = 15) to 209 ± 9 µl(n = 9). Furthermore, indomethacin lowered exudation rates significantly throughout the time course up to 16 h in WT mice (Fig. 1C); it decreased the peak exudation rate at 3 h from 104 ± 13 (n = 12) to 67 ± 11 µl/20 min (n = 7), indicating again that prostanoids are involved in the facilitation of vascular permeability. It is noteworthy that indomethacin treatment showed no significant effect on the exudate volume (Fig. 1B) or the exudation rate (Fig. 1D) in IP–/– mice. Furthermore, exudate volume and the exudation rate in IP–/– mice were almost the same as those in indomethacin-treated WT mice, indicating that PGI2 is a major prostanoid involved in enhanced exudate formation in the present model of zymosan-induced pleurisy.
There was no significant difference in the number of pleural resident cells, consisting almost of mononuclear cells, between WT and IP–/– mice, 2.0 ± 0.1 x 106 (n = 7) and 1.9 ± 0.3 x 106 (n = 7), respectively. In WT mice, the leukocyte number in the exudates did not change at 1 h, it increased gradually up to 8 h, and it remained at a steady level thereafter (Fig. 1E), indicating that leukocyte recruitment starts later than exudate formation, although it occurs at a relatively early phase of zymosan-induced pleurisy. After 8 h, infiltrated cells were composed of 
90% neutrophils and the remaining mononuclear cells, indicating that neutrophils are the main cell type recruited in zymosan-induced pleurisy. In contrast to the significant differences found in the exudate volume and exudation rate, there was no significant difference in leukocyte number in the exudates for WT and IP–/– mice (Fig. 1, E and F), excluding the involvement of IP in leukocyte recruitment. Furthermore, indomethacin treatment had no significant effect on leukocyte number throughout the time course of both WT and IP–/– mice (Fig. 1, E and F), indicating that PGs, including PGI2, do not play a major role in leukocyte migration in zymosan-induced pleurisy. As a result, we focused our investigation on the regulation of exudate formation in zymosan-induced pleurisy in the following experiments.
Zymosan-Induced Pleurisy in EP–/– Mice. The findings in zymosan-induced pleurisy in IP–/– mice, as well as the effect of indomethacin on pleurisy, suggested that PGI2 is a major prostanoid component in zymosan-induced pleurisy. To further determine whether PGE2, another representative prostanoid mediating a variety of inflammatory responses, contributes to zymosan-induced pleurisy, pleurisy was induced in EP receptor knockout mice: EP1–/–, EP2–/–, EP3–/–, and EP4–/– mice. The peak exudate volumes at 5 h were similar in all EP–/– groups, and these values were not significantly different from those of WT mice (Fig. 2A). Indomethacin treatment significantly suppressed exudate formation at 5 h in all EP–/– groups to levels similar to those in WT mice (Fig. 2A). Similar results were also obtained in the exudate volumes at an earlier time point of 1 h (data not shown). Accordingly, exudation rates at 1 h were similar in all the EP–/– groups, and these values did not differ significantly from those in WT mice (Fig. 2B). Indomethacin also significantly attenuated exudation rates at 1 h in all EP–/– groups to levels similar to those in WT mice (Fig. 2B). There was no significant difference in zymosan-induced exudate formation between WT and F2-WT mice (data not shown). These results clearly indicate that PGE2 does not play a role in the present model of zymosan-induced pleurisy.
|
Measurement of PGs in the Exudates. To clarify the reason for the differential involvement of PGI2 and PGE2 in zymosan-induced pleurisy, we measured the contents of 6-keto-PGF1 and PGE2 in the exudates at 1, 3, 5, and 24 h of zymosan-induced pleurisy. The contents of 6-keto-PGF1 had already increased at 1 h, they stayed at a peak level of 30 ng/mouse for at least up to 5 h, and they remained at a significant level even at 24 h (Fig. 3A). Estimated 6-keto-PGF1 concentrations in the exudates at 1 h were around 0.5 µM, a well working range of the PGI2-IP system. In contrast to the prominent production of PGI2, PGE2 production was almost negligible, and the level of PGE2 in the exudates was 1/20 to 1/30 of that of 6-keto-PGF1 at 3 and 5 h (Fig. 3B). This result suggests that preferential production of PGI2 in the pleural cavity supports PGI2 to be the main component in zymosan-induced pleurisy. Indomethacin treatment significantly reduced the levels of both 6-keto-PGF1 and PGE2 to barely detectable (Fig. 3, A and B), indicating almost complete COXs suppression by indomethacin.
|
), decreased peak exudate volume at 5 h significantly from 522 ± 25 to 150 ± 25 µl (Fig. 4A). Accordingly, the peak exudation rate at 3 h was suppressed significantly by SC58125 from 116 ± 36 to 36 ± 2 µl/20 min (Fig. 4B). These SC58125-suppressed levels of exudate volume and the exudation rate were almost the same as those in IP–/– mice (Fig. 1, B and D). Furthermore, the inhibitory effects of SC58125 on exudate formation were comparable with those of indomethacin (Fig. 1, A and C), suggesting that COX-2 is a responsible isoform producing PGI2 in the present pleurisy model.
|
Involvement of the Complement System in Zymosan-Induced Pleurisy. To determine whether the complement system is activated in zymosan-induced pleurisy, pleural exudates and blood were collected, and they were examined for activation of the complement system using C3 activation as a marker. In the saline wash of the pleural cavity at 0 h, slight activation of the complement system represented by the presence of iC3b(a) and iC3b(b) segments was observed, showing spontaneous activation of C3 (Lachmann and Hughes-Jones, 1984). Although the bands in the lane at 0 h were apparently strong, absolute protein levels at this time point were much smaller, and they were 1/5 to 1/10 of those in the exudates at later time points, indicating that actual amounts of activated C3 was not so large at a basal condition. However, as early as 1 h, apparent activation of the complement system was observed in pleural exudates, as shown by an increase in iC3b(b) segment and the appearance of C3dg and C3c segments, degradation products of iC3b, which activation was observed up to 16 h (Fig. 5A). Because the production of iC3b(a) segment is dependent on the balance between the production and degradation of iC3b, amounts of iC3b(a) were apparently constant (Fig. 5A). In contrast, activation of the complement system was not observed in plasma up to 16 h, although a lesser extent of spontaneous activation of C3 was observed (Fig. 5B), indicating that the complement system was activated within the pleural cavity.
|
|
No Involvement of PAF in Exudate Formation in Zymosan-Induced Pleurisy. Although PGI2 and complement play essential roles in zymosan-induced pleurisy, simultaneous treatment with indomethacin and CVF did not suppress exudate formation completely, indicating that other factor(s) is involved in zymosan-induced pleurisy. Therefore, we finally examined whether PAF participates in exudate formation. In WT mice, C16-PAF and MC-PAF, a PAF analog resistant to metabolic degradation, induced exudate accumulation after being injected into the pleural cavity (Fig. 7A), indicating that PAF works as a potent inflammatory mediator that increases vascular permeability. PAF- and MC-PAF-induced formations of pleural exudates were suppressed significantly by pretreatment with a PAF receptor antagonist TCV-309 (Fig. 7A). Moreover, C16-PAF and MC-PAF did not induce exudate formation in PAFR–/– mice (Fig. 7A), indicating that effects of PAF analogs were mediated exclusively by the PAF receptor. However, in zymosan-induced pleurisy, TCV-309 pretreatment did not show any suppressive effect on the exudate volumes at 3 and 5 h (Fig. 7B). Furthermore, there was no significant difference in the exudate volumes between WT and PAFR–/– mice at 3 and 5 h (Fig. 7B). These results clearly indicate that PAF plays an insignificant, if at all any, role exudate formation in the present zymosan-induced pleurisy model.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
In the present study, selective involvement of IP, but not EPs, could be supported by a preferential production of PGI2 compared with that of PGE2 in the pleural cavity (Fig. 3). Low level of PGE2 production was unexpected, because abundant PGE2 production by zymosan-stimulated mouse peritoneal macrophages in vitro has been reported (Scott et al., 1980; Suram et al., 2006). However, resident peritoneal macrophages produced much greater amounts of prostanoids than elicited macrophages when stimulated by zymosan in vitro (Humes et al., 1980), indicating that production of prostanoids depends on the conditions of the macrophages prepared. Furthermore, infiltrated leukocytes affected the types of prostanoids produced by macrophages in zymosan-induced mouse peritonitis in vivo (Tripp et al., 1986), indicating that the types of prostanoids produced in response to zymosan in vivo would differ from those produced in vitro. In fact, selective production of PGI2 has been reported in zymosan-induced mouse peritonitis in vivo (Lundy et al., 1990; Rao et al., 1994), indicating along with our results that the major prostanoid produced in zymosan-induced responses in vivo is PGI2. In relation to this, it should be noted that the level of PGI2 production in the present zymosan-induced pleurisy model was 10 times higher than that in the mouse pleurisy model induced by carrageenin (Yuhki et al., 2004), a potent activator of the kinin system.
In the present model, PGI2 production depended mainly on COX-2, an inducible isoform of COXs (Fig. 4). Accordingly, COX-2 has been reported to be significantly up-regulated with resultant prostanoid production in zymosan-stimulated peritoneal macrophages (Suram et al., 2006). It is interesting to note that a COX-2 inhibitor suppressed only a small part of PG production in lipopolysaccharide-pretreated, zymosan-stimulated peritoneal macrophages in vitro, whereas augmented PG production induced by an addition of exogenous arachidonic acid totally depended on COX-2, suggesting a more preferential usage of exogenous arachidonate by COX-2 (Rouzer and Marnett, 2005). These results indicate the possibility that COX-2 uses arachidonic acid, which is released abundantly into pleural exudates as reported in zymosan-induced peritonitis (Lundy et al., 1990), as a substrate to produce PGI2 in the present pleurisy model.
In contrast to the important role of the PGI2-IP system in the regulation of exudate formation, involvement of prostanoids, including PGI2, in leukocyte recruitment into the pleural cavity is unlikely (Fig. 1, E and F). This result indicates that leukocyte recruitment occurs independently of an increase in vascular permeability and that factor(s) other than prostanoids works as a chemoattractant for the leukocytes, especially for neutrophils. As such a factor, LTB4, the most potent chemoattractant known for neutrophils, was reported to be responsible for neutrophil recruitment in zymosan-induced mouse peritonitis (Byrum et al., 1999). Furthermore, a critical role for LTB4 in neutrophil recruitment was reported in zymosan-induced mouse pleurisy (Takeshita et al., 2003), indicating an important role for an eicosanoid other than prostanoids in mediating zymosan-induced responses. However, another factor might be involved in neutrophil recruitment, because cytokine-induced neutrophil chemoattractant was found to increase in pleural exudates at an early phase of zymosan-induced rat pleurisy (Utsunomiya et al., 1998). In recent studies, the anti-inflammatory role of PGI2 via the effects on dendritic and Th2 cells in a mouse asthma model has been reported (Idzko et al., 2007; Jaffar et al., 2007), indicating direct action of PGI2 on immune-mediating cells. Although participation of these PGI2 actions in zymosan-induced pleurisy is still unclear and remains to be determined, it might contribute to infiltration and activation of leukocytes in the present pleurisy model.
The complement system is another important effector system and mediates zymosan-induced innate immune responses (Morgan and Harris, 2003). The activated complement system generates anaphylatoxins, C3a and C5a, which play an important role in vascular permeability increase, as well as in leukocyte migration (Guo and Ward, 2005). In the present zymosan-induced pleurisy model, we confirmed the apparent activation of the complement system within the pleural cavity without an apparent activation of plasma C3 (Fig. 5). This indicates that the complement system was activated locally within the pleural cavity after blood complements had leaked into there, suggesting that an initial factor increasing vascular permeability would be required to induce a subsequent activation of the complement system. Accordingly, simultaneous treatment with CVF and indomethacin suppressed exudate formation more than each treatment alone in WT mice (Fig. 6), indicating that the PGI2-IP system and the complement system work together along with their independent actions in zymosan-induced exudate formation. This cooperation may result from the interrelation between the two systems so that initial production of PGI2 by zymosan-stimulated macrophages and the resultant increase in vascular permeability would be required for a subsequent activation of the complement system in the pleural cavity; and conversely, the activated complement components, such as C3a and C5a (Cooper et al., 1980), would further stimulate PGI2 production by macrophages.
Although a cooperative action of PGI2 and the complement explained more than 70% of exudate formation, a small residual part was suggested to be mediated by other factor(s). PAF was a promising candidate as such a mediator, because it participated in exudate formation in zymosan-induced rat pleurisy (Imai et al., 1991). However, in the present study, we could not detect any involvement of PAF in zymosan-induced exudate formation (Fig. 7), and insufficient production of PAF in response to zymosan was suggested. Although the precise mechanism of this species difference in rat and mouse is not clear and remains to be studied, there are some species differences in the expression pattern of phospholipase A2 that play an important role in PAF biosynthesis (Kudo and Murakami, 2002). Other candidates participating in zymosan-induced responses include cysteinyl LTs, potent enhancers of vascular permeability. Accordingly, significant amounts of LTC4 were shown to be produced by peritoneal macrophages in vitro (Tripp et al., 1986) and in zymosan-induced peritonitis in vivo (Lundy et al., 1990; Rao et al., 1994). Furthermore, the zymosan-induced i.p. extravasation of plasma protein was significantly diminished in mice lacking LTC4 synthase (Kanaoka et al., 2001), suggesting the possibility that cysteinyl LTs are responsible for residual exudate formation remaining after simultaneous treatment with indomethacin and CVF in the present study.
Several investigators have reported the participation of prostanoids in fungal infection. Pathogenic fungi, such as Cryptococcus neoformans and Candida albicans, produced several types of prostanoids, and their growth was inhibited significantly by COX inhibitors (Noverr et al., 2001). In addition, survival of mice infected with C. albicans was significantly increased by treatment with LAAE-14, a novel anti-inflammatory drug that inhibits prostanoid synthesis (Lucas et al., 2004), suggesting the participation of prostanoids in the pathogenesis of fungal infection. Interestingly, it is known that fungal infection is prone to be chronic and disseminating if the Th1-Th2 balance of cellular immunity is shifted toward Th2 preference (Romani and Kaufmann, 1998). Considering the proinflammatory effect of PGI2 presented in the present study and the suppressive actions of PGI2 on Th2 responses (Idzko et al., 2007; Jaffar et al., 2007), PGI2 might affect the course of fungal infection via these effects. However, the precise role of the PGI2-IP system in the pathogenesis of fungal infection remains to be determined.
In conclusion, the present study clearly demonstrated the key role of the PGI2-IP system together with the complement system in zymosan-induced mouse pleurisy. This contributes to a better understanding of the mechanisms working in the zymosan-induced innate immune responses.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: PG, prostaglandin; LT, leukotriene; PAF, platelet-activating factor; PAFR, PAF receptor; COX, cyclooxygenase; SC58125, 5-(4-fluorophenyl)-1-[4-(methylsulfonyl)phenyl]-3-(trifluorophenyl)-1H-pyrazole; EP, PGE2 receptor; EP–/–, EP-knockout; WT, wild type; PAGE, polyacrylamide gel electrophoresis; CVF, cobra venom factor; IP, PGI2 receptor; IP–/–, IP-knockout; C16-PAF, 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine; MC-PAF, 1-O-hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphocholine; TCV-309, 3-bromo-5-[N-phenyl-N-[2-(1,2,3,4-tetrahydro-2-isoqunolylcarbonyloxy) ethyl]carbamoyl]-1-propylpyridinium nitrate; Th, T helper; LAAE-14, lipidic acid-amino ether derivative 14.
Address correspondence to: Dr. Koh-ichi Yuhki, Department of Pharmacology, Asahikawa Medical College, 2-1-1-1 Midorigaoka-Higashi, Asahikawa 078-8510, Japan. E-mail: yukik{at}asahikawa-med.ac.jp
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Brown GD and Gordon S (2001) A new receptor for β-glucans. Nature 413: 36–37.[Medline]
Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, and Koller BH (1999) Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice. J Immunol 163: 6810–6819.
Cochrane CG, Muller-Eberhard HJ, and Aikin BS (1970) Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol 105: 55–69.
Cooper JD, McDonald JW, Ali M, Menkes E, Masterson J, and Klement P (1980) Prostaglandin production associated with the pulmonary vascular response to complement activation. Surgery 88: 215–221.[Medline]
Dozen M, Yamaki K, and Oh-ishi S (1989) Captopril uncovers kinin-dependent release of arachidonic acid metabolites in carrageenin-induced rat pleurisy. Jpn J Pharmacol 51: 101–105.[Medline]
Fujita T, Matsushita M, and Endo Y (2004) The lectin-complement pathway–its role in innate immunity and evolution. Immunol Rev 198: 185–202.[CrossRef][Medline]
Gordon S (2002) Pattern recognition receptors: doubling up for the innate immune response. Cell 111: 927–930.[CrossRef][Medline]
Guo R-F and Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821–852.[CrossRef][Medline]
Harada Y, Tanaka K, Uchida Y, Ueno A, Oh-ishi S, Yamashita K, Ishibashi M, Miyazaki H, and Katori M (1982) Changes in the levels of prostaglandins and thromboxane and their roles in the accumulation of exudates in rat carrageenin-induced pleurisy–a profile analysis using gas chromatography-mass spectrometry. Prostaglandins 23: 881–895.[CrossRef][Medline]
Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N, et al. (1999) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. Proc Natl Acad Sci U S A 96: 10501–10506.
Humes JL, Burger S, Galavage M, Kuehl FA Jr, Wightman PD, Dahlgren ME, Davies P, and Bonney RJ (1980) The diminished production of arachidonic acid oxygenation products by elicited mouse peritoneal macrophages: possible mechanisms. J Immunol 124: 2110–2116.[Medline]
Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, and Lambrecht BN (2007) Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 117: 464–472.[CrossRef][Medline]
Imai Y, Hayashi M, and Oh-ishi S (1991) Key role of complement activation and platelet-activating factor in exudate formation in zymosan-induced rat pleurisy. Jpn J Pharmacol 57: 225–232.[Medline]
Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao WH, Kume K, Fukuchi Y, Ikuta K, et al. (1998) Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 187: 1779–1788.
Jaffar Z, Ferrini ME, Buford MC, FitzGerald GA, and Roberts K (2007) Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. J Immunol 179: 6193–6203.
Kanaoka Y, Maekawa A, Penrose JF, Austen KF, and Lam BK (2001) Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem 276: 22608–22613.
Kudo I and Murakami M (2002) Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68–69: 3–58.
Lachmann PJ and Hughes-Jones NC (1984) Initiation of complement activation. Springer Semin Immunopathol 7: 143–162.[CrossRef][Medline]
Lucas R, Villamon E, Paya M, Alves M, del Olmo E, Gozalbo D, and Gil ML (2004) LAAE-14, a new anti-inflammatory drug, increases the survival of Candida albicans-inoculated mice. FEMS Immunol Med Microbiol 40: 239–242.[CrossRef][Medline]
Lundy SR, Dowling RL, Stevens TM, Kerr JS, Mackin WM, and Gans KR (1990) Kinetics of phospholipase A2, arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis. J Immunol 144: 2671–2677.[Abstract]
Morgan BP and Harris CL (2003) Complement therapeutics; history and current progress. Mol Immunol 40: 159–170.[CrossRef][Medline]
Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678–682.[CrossRef][Medline]
Narumiya S, Sugimoto Y, and Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193–1226.
Noverr MC, Phare SM, Toews GB, Coffey MJ, and Huffnagle GB (2001) Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun 69: 2957–2963.
Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, and Wardlaw AC (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279–285.
Rao TS, Currie JL, Shaffer AF, and Isakson PC (1994) In vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Ther 269: 917–925.
Rocha e Silva M (1978) A brief history of inflammation, in Handbook of Experimental Pharmacology (Vane JR and Ferreira SH eds) vol. 50/I, pp 6–25, Springer-Verlag, Berlin.
Romani L and Kaufmann SHE (1998) Immunity to fungi: editorial overview. Res Immunol 149: 277–281.[CrossRef][Medline]
Rouzer CA and Marnett LJ (2005) Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. J Biol Chem 280: 26690–26700.
Scott WA, Zrike JM, Hamill AL, Kempe J, and Cohn ZA (1980) Regulation of arachidonic acid metabolites in macrophages. J Exp Med 152: 324–335.
Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, Hirose M, et al. (1998) Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 246: 7–12.[CrossRef][Medline]
Suram S, Brown GD, Ghosh M, Gordon S, Loper R, Taylor PR, Akira S, Uematsu S, Williams DL, and Leslie CC (2006) Regulation of cytosolic phospholipase A2 activation and cyclooxygenase 2 expression in macrophages by the β-glucan receptor. J Biol Chem 281: 5506–5514.
Takeshita K, Sakai K, Bacon KB, and Gantner F (2003) Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 307: 1072–1078.
Tripp CS, Unanue ER, and Needleman P (1986) Monocyte migration explains the changes in macrophage arachidonate metabolism during the immune response. Proc Natl Acad Sci U S A 83: 9655–9659.
Underhill DM (2003) Macrophage recognition of zymosan particles. J Endotoxin Res 9: 176–180.[Medline]
Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, et al. (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281–284.[CrossRef][Medline]
Utsunomiya I, Ito M, and Oh-ishi S (1998) Generation of inflammatory cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6 and cytokine-induced neutrophil chemoattractant (CINC) in vivo. Cytokine 10: 956–963.[CrossRef][Medline]
Vane JR, Bakhle YS, and Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120.[CrossRef][Medline]
Vinegar R, Truax JF, and Selph JL (1973) Some quantitative temporal characteristics of carrageenin-induced pleurisy in the rat. Proc Soc Exp Biol Med 143: 711–714.[CrossRef][Medline]
Yuhki K, Ueno A, Naraba H, Kojima F, Ushikubi F, Narumiya S, and Oh-ishi S (2004) Prostaglandin receptors EP2, EP3, and IP mediate exudate formation in carrageenin-induced mouse pleurisy. J Pharmacol Exp Ther 311: 1218–1224.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
, p < 0.05 compared with a group pretreated with CVF. C, effects of CVF pretreatment on the exudate volume in EP–/– mice in zymosan-induced pleurisy. CVF (10 µg) was i.p. injected 24 h before the zymosan injection. The exudate volume was measured at 3 h after the zymosan injection. CVF, CVF pretreatment. Data represent the mean ± S.E.M. of the values obtained from five to 10 mice. *, p < 0.05 compared with each CVF-nontreated control group.